Speaker

中文版
石远凯
肿瘤学博士，肿瘤内科主任医师，中国医学科学院北京协和医学院长聘教授。
国家药品监督管理局药品注册审评专家咨询委员会委员
The Lancet Oncology International Adversary Board Member（2017年11月－2020年12月）
进行抗肿瘤药物及相关临床研究400余项，作为主要研究者完成了13个新药和生物类似药的关键注册临床试验，使这些药物上市
以第一和/或通讯作者（含共同）在国内外期刊上发表文章452篇
爱思唯尔中国高被引学者（2020年、2021年、2022年、2023年）
全球前2%顶尖科学家（2021年、2022年、2023年、2024年）

英文版
Yuankai Shi, MD
Professor of medical oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College The tenure-track professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Member of the advisory committee of the New Drug Evaluation, National Medical Products Administration, China. International Adversary Board member of The Lancet Oncology(2017.11-2020.12).

As the principal investigator or participator, he has taken part in over 400 clinical trials and related research projects of anti-cancer drugs, and completed the pivotal registration trails for 13 new anti-cancer drugs or biosimilars, and made them approved on the market.
As the first and/or corresponding author including co-first and/or co-corresponding author, he has published over 452 articles in the international or domestic medical journals.

Highly Cited Chinese Researchers by Elsevier in 2020, 2021, 2022 and 2023.
The World’s Top 2% Scientists in 2021, 2022, 2023 and 2024.